N-取代肌肽酰胺类衍生物的合成及生物活性

以肌肽为原料,对伯氨基进行了结构修饰,合成了11种肌肽衍生物.化合物的结构经核磁共振、紫外-可见光谱及高分辨质谱分析确证.丙烯醛清除活性测试结果表明,在实验浓度下大部分化合物表现出一定的清除丙烯醛活性,尤其是化合物4k对丙烯醛的清除活性高于肌肽.脾细胞增殖活性测试结果表明,在实验浓度下大部分化合物表现出一定的脾细胞增殖活性,特别是化合物4b,4d和4k对脾细胞的增殖活性高于阳性对照伴刀豆球蛋白A.过氧化氢诱导血管内皮细胞损伤的预保护实验结果表明,在实验浓度下大部分化合物表现出一定的预保护作用,其中化合物4a,4j和4k对过氧化氢诱导血管内皮细胞损伤的预保护作用大于肌肽.血浆稳定性实验结果表明,与肌肽相比,11种化合物均具有很好的血浆稳定性.     

氟康唑衍生物的设计合成及体外抗真菌活性研究

为了寻找活性更好的抗真菌化合物,基于已有的计算机辅助药物设计结果,保留氟康唑母体结构必需药效团,设计、合成了22个含对甲酚和胸腺嘧啶的氟康唑新衍生物.目标化合物的结构经1H NMR、元素分析和ESI-MS确证,初步体外抗真菌活性试验结果表明,化合物5l对7种真菌都表现出了较好的抗真菌活性(烟曲霉菌除外),化合物5a～5e,5g,5h,7a和7b对不同真菌表现出了一定的抗真菌活性.炔丙基取代氨基侧链结构的引入有利于提高该类目标化合物体外抗真菌活性,值得进一步深入研究.     

新型1,2,3-三唑类化合物的合成及抗菌构效关系

根据活性基团拼接原理, 以4-取代-苯胺为原料, 经重氮化、 关环和缩合反应合成了17个化合物1-(4-取代苯基)-5-取代苯基亚氨基-4-取代-1,2,3-三唑(7a~7c和13a~13d)和1-(4-取代苯基)-5-取代苄基氨基-4-取代-1,2,3-三唑(5a~5c, 10a~10c和14a~14d), 其中化合物5a~5c, 7b, 7c, 10a, 10c, 13b~13d和14b~14c为新化合物, 对所制备化合物的结构进行了表征. 生物活性测试结果表明, 所有化合物均表现出一定的抑菌活性, 对大肠杆菌的抑菌活性均优于氟康唑; 化合物7a和10c对金黄色葡萄球菌的抑制活性明显优于氟康唑; 而化合物13a和13d则对白色念球菌表现出良好的抑制活性, 与三氯生相当.     

双三唑硫醚席夫碱的合成及抗菌活性研究

席夫碱类化合物及其金属配合物具有一定的药理学和生理学活性[1-4].三唑硫醚类化合物具有较好的抗菌活性[5],作者为了初步筛选出抗菌活性较好的目标化合物,并得到抗菌活性较好的先导体,本文设计合成了一系列的硫醚类新型多杂环化合物(a～f),用IR、1H NMR、MS和元素分析进行了结构表征,其合成路线如下.     

大黄素衍生物的合成及抗癌活性

通过对大黄素的C6位进行化学修饰, 设计合成了7个含氮杂环的大黄素衍生物和3个含季铵盐基团的大黄素衍生物. 通过红外光谱、 ¹H NMR和质谱表征了所制备化合物的结构, 并测试了它们对白血病细胞Molt-4和淋巴瘤细胞CA46的体外抑制活性. 其中化合物8, 9a+9b, 20a, 20b和20c均显示出比大黄素更高的抗癌活性, 表明苯并咪唑基团和季铵盐基团是大黄素提高抗癌活性的有效药效团.     

胱胺衍生物的合成及抗非小细胞肺癌活性研究

为寻求活性强的非小细胞肺癌(NSCLC)药物,设计合成了一系列胱胺衍生物4a～4g,并对其抗NSCLC活性进行了初步探讨.以胱胺为起始原料,经过加成、还原反应得到了目标化合物,采用CCK-8法对其抗NSCLC细胞增殖活性进行了测试.目标化合物4a～4g结构经ESI-MS、1 H-NMR、13 C-NMR谱确证.活性结果...     

基于咔唑的单-/双-硫代碳酰腙衍生物的合成及Cdc25B/PTP1B抑制活性评价

合成了一系列新型的基于咔唑的单-/双-硫代碳酰腙衍生物.利用IR、1H NMR、13C NMR和元素分析对其进行了结构表征.评价了目标化合物对Cdc25B和PTP1B的抑制活性,讨论了其结构与活性的关系.实验结果显示,大部分目标化合物对Cdc25B和PTP1B表现出良好的抑制活性.其中,1,5-双[(9-戊基-3-咔唑基)亚甲基]硫代碳酰腙(4d)对Cdc25B的抑制活性最高,IC50为(0.23±0.02)μg/m L.1,5-双[(9-乙基-3-咔唑基)亚甲基]硫代碳酰腙(4a)对PTP1B的抑制活性最高, IC50为(1.00±0.16)μg/m L.对目标化合物4a和4d进行分子对接研究和密度泛函理论(DFT)计算,结果表明,目标化合物4d和4a分别进入到了Cdc25B和PTP1B酶的活性位点区域,有活性作用的主要是硫代碳酰腙和咔唑基团.     

6,7-二甲氧基-4-哌嗪喹唑啉缩氨基硫脲衍生物的合成及体外抗肿瘤活性研究

以4,5-二甲氧基-2-氨基苯甲酸和醋酸甲眯为起始原料,经环化、氯化、取代和缩合四步反应,设计、合成了六个未见文献报道的含有缩氨基硫脲的喹唑啉衍生物4a～4f,其结构用1H NMR,13C NMR,ESI-MS,IR及元素分析测试技术进行了表征.采用MTT法测试了化合物4a～4f对人胃癌SGC-7901、人口腔表皮样癌KB和人纤维肉瘤HT-1080的体外抗肿瘤活性.初步的测试结果表明,化合物4a和4f对HT1080表现出显著的抗肿瘤活性.     

3位苯甲酰腙和亚氨基取代硫脲取代的吲哚满二酮衍生物的合成及对AHAS的抑制活性

基于前期生物设计AHAS抑制剂的研究,设计合成了15个吲哚满二酮类衍生物,其中9个为新化合物,其结构均经过1H NMR,MS和元素分析确证,并对所有化合物进行了离体和活体活性测试.实验结果表明,这类化合物在体内和体外均具有一定的生物活性,在离体活性测试中,所有化合物在100μg/mL浓度下对拟南芥AHAS均表现出明确的抑制活性,其中化合物4d,4e,5a和5f在10μg/mL浓度下仍然对AHAS表现出45%以上的抑制率,但此类化合物除草活性普遍较差.     

新型吡啶-2-酮类衍生物的合成及生物活性

以3-氰基-5-乙酰基-6-甲基吡啶-2-酮(1a～1b)为原料,通过多步反应,合成了18种未见报道的含有均三唑并[3,4-b][1,3,4]噻二嗪或1,3,4-噁二唑啉的两类新型吡啶酮类化合物4a～4h,7a～7j,其结构经1H NMR,IR和MS及元素分析确证.利用单晶X射线衍射法测定了化合物4a的晶体结构.初步生测表明,部分化合物表现出不同的抗菌活性.     

Electrodriven methods for the enantioseparation of second-generation antidepressant drugs: an update

Second-generation antidepressant drugs are increasingly prescribed world-wide by psychiatrists and primary care physicians. Generally speaking, they seem to be safer than traditional tricyclic antidepressant drugs, especially in overdose. However, most of them possess stereogenic centers, thus they can exist as enantiomeric couples. Since enantiomers can have even dramatically different pharmacokinetic and pharmacodynamic properties, the study of antidepressant chirality is of great importance. In fact, the application of enantioselective analytical techniques can be useful both for the quality control of enantiomerically pure formulations and for the pharmacovigilance and therapeutic monitoring of patients undergoing treatment with these drugs. The high efficiency and inexpensiveness of electrodriven methods makes them a very attractive alternative to the usual chromatographic methods. This review is an update (2004-2007) of a previously published paper on recent electrodriven methods for the enantioseparation of second-generation antidepressants. In particular, the focus has been put on selective serotonin reuptake inhibitors such as citalopram and sertraline, noradrenergic and specific serotonergic antidepressants, such as mirtazapine and tetracyclic antidepressants such as mianserin, as well as on multianalyte methods.     

Advances in the enantioseparation of second-generation antidepressant drugs by electrodriven methods

Stereochemistry is steadily increasing in importance in the development of new drugs, and the availability of pure enantiomer drugs can make therapy safer and more efficacious. In particular, almost all second-generation antidepressant drugs possess one or more chiral centres; however, only some of them are administered as single enantiomers. A fundamental part of the quality control of pharmaceutical formulations is the determination of enantiomeric excess and enantiomeric purity; this is also important for the therapeutic drug monitoring of depressed patients. For this purpose, efficient and reliable analytical methods are needed and electrodriven techniques (most of all CE, CEC and MEKC) are very efficient and inexpensive candidates for the role. In this review, the enantioselective electrodriven methods available for the analysis of second-generation antidepressant are presented and discussed. In particular, the following pharmacological classes of antidepressants will be considered: selective serotonin reuptake inhibitors (fluoxetine, citalopram, paroxetine, sertraline); norepinephrine reuptake inhibitors (reboxetine); serotonin and norepinephrine reuptake inhibitors (venlafaxine, milnacipran, duloxetine); and noradrenergic and specific serotonergic antidepressants (mirtazapine).     

The Microglial Activation Inhibitor Minocycline,Used Alone and in Combination with Duloxetine,Attenuates Pain Caused by Oxaliplatin in Mice

The antitumor drug, oxaliplatin, induces neuropathic pain, which is resistant to available analgesics, and novel mechanism-based therapies are being evaluated for this debilitating condition. Since activated microglia, impaired serotonergic and noradrenergic neurotransmission and overexpressed sodium channels are implicated in oxaliplatin-induced pain, this in vivo study assessed the effect of minocycline, a microglial activation inhibitor used alone or in combination with ambroxol, a sodium channel blocker, or duloxetine, a serotonin and noradrenaline reuptake inhibitor, on oxaliplatin-induced tactile allodynia and cold hyperalgesia. To induce neuropathic pain, a single dose (10 mg/kg) of intraperitoneal oxaliplatin was used. The mechanical and cold pain thresholds were assessed using mouse von Frey and cold plate tests, respectively. On the day of oxaliplatin administration, only duloxetine (30 mg/kg) and minocycline (100 mg/kg) used alone attenuated both tactile allodynia and cold hyperalgesia 1 h and 6 h after administration. Minocycline (50 mg/kg), duloxetine (10 mg/kg) and combined minocycline + duloxetine influenced only tactile allodynia. Seven days after oxaliplatin, tactile allodynia (but not cold hyperalgesia) was attenuated by minocycline (100 mg/kg), duloxetine (30 mg/kg) and combined minocycline and duloxetine. These results indicate a potential usefulness of minocycline used alone or combination with duloxetine in the treatment of oxaliplatin-induced pain.     

磁性固相萃取在检测抗抑郁药中的应用进展

作为治疗抑郁、焦虑、强迫等精神障碍疾病的主要药物,抗抑郁药的消耗量逐年增大。针对涉及抗抑郁药滥用的各类案件,物证鉴定人员需对药物的种类及含量进行分析。为准确、灵敏地检测实际检材中的抗抑郁药,样品前处理过程必不可少。磁性固相萃取采用比表面积大、分散性能好、可重复使用的各类功能化磁性材料作为吸附剂,因操作简单快速、萃取效率高、成本较低而被广泛用于各种生物检材中痕量目标分析物的分离富集。本文对近年来以磁性固相萃取为前处理技术检测抗抑郁药的研究进行综述,旨在为法庭科学领域相关实践办案和科学研究提供参考。     

Photophysics and photochemistry of imipramine, desimipramine, and clomipramine in several solvents: a fluorescence, 266 nm laser flash, and theoretical study

Imipramine (IPA) and its derivatives are used widely for the treatment of depression and other mental disorders. Although there are more than 20 FDA-approved antidepressant drugs, the search continues for better compounds with fewer deleterious side effects and higher efficacy. Over the past decade, several classes of antipsychotic drugs have been developed, which-in spite of their structural diversity-share an ability to modulate neurotransmission and to produce undesirable side effects. Phototoxicity is one of the most important side effects noted in treatment with tricyclic antidepressants (TCAs), but its mechanism has not yet been elucidated. To develop new knowledge regarding the relationship between the structure and the photophysics of these TCAs, we measured the photophysical properties of IPA, desimipramine (DIPA), and clomipramine (CIPA) in different solvents. The electronic configurations for the ground and the first excited singlet states were calculated using the AM1/RHF/CI and the AM1/RHF/HE semiempirical quantum theoretical methods, respectively. The ground-state properties are solvent-independent, while the emission maxima are red-shifted with increasing solvent polarity/polarizability. However, the fluorescence quantum yield is relatively low in all of the tested solvents (phif<0.02). The primary transient intermediates produced by 266 nm high-intensity laser photolysis are the solvated electron and the corresponding radical cation, with a negligible contribution of triplet-triplet absorption. The properties determined for the primary transients generated with a 266 nm laser flash are consistent with the photodamaging effects generated through a limited radical mechanism.     

Modern chromatographic and electrophoretic measurements of antidepressants and their metabolites in biofluids

Depression is one of the most frequently occurring psychiatric conditions affecting the economic and social functioning of people all over the world. There are a few classes of drugs commonly used to treat patients with depression disorders. Therapeutic drug monitoring of antidepressants provides the possibility to reduce side effects and optimize the treatment of patients with depression. Hence, there is a need to develop reliable analytical methods for the determination of these agents in biological fluids. Moreover, an important part of understanding the mechanisms of action of these medicines is also associated with the recognition of the metabolites' function because of their potential influence on therapeutic benefits and/or adverse effects. Some of them possess the same primary activity as their parent compounds and may contribute to the therapeutic efficacy whereas the biochemical actions of other metabolites may be different from that of the parent drug. In this review, several validated high-performance liquid chromatographic, gas chromatographic and capillary electrophoretic methods for quantification of antidepressants and their metabolites in biofluids are compared. In addition, the review covers areas such as mechanism of actions, structure-activity relationships and metabolism of the cited antidepressants.     

Determination of antidepressants in surface and waste water samples by capillary electrophoresis with electrospray ionization mass spectrometric detection after preconcentration using off-line solid-phase extraction

A method for the quantitative determination of seven major antidepressants in surface waters and sewage treatment plant effluents by CE using ESI-MS is presented. Calibration curves for the selected analytes were prepared in Milli-Q purified water and Danube river water extract covering a concentration range of at least one order of magnitude. LODs achieved were between 6 and 13 microg/L for Trazodone and 39 and 53 microg/L for Sertraline in the Milli-Q purified water and Danube river water matrix, respectively. For sample preparation eight different SPE materials were investigated. Best results were obtained for a resin based on hydrophilic divinylbenzene (recoveries from Milli-Q purified water 93-96%; from Danube river water 85-99%). Finally, a series of eight sewage treatment plant effluents were investigated with respect to their content in the selected antidepressants. Six of these samples were tested positive for antidepressants, in particular Venlafaxine, Citalopram and Trazodone in concentrations between 36 and 322 ng/L.     

Synthesis of novel 5-HT1A arylpiperazine ligands: Binding data and computer-aided analysis of pharmacological potency

Serotonin receptors modulate numerous behavioral and neuropsychological processes. Therefore, they are the target for the action of many drugs, such as antipsychotics, antidepressants, antiemetics, migraine remedies, and many others. The 5-HT1A receptors have been involved in the pathogenesis and treatment of anxiety and depression and represent a promising target for new drugs with reduced extrapyramidal side effects. In most antidepressants, a piperazine-based structural motif can be identified as a common moiety. Here we describe the synthesis, pharmacological, and in silico characterization of a novel arylpiperazines series with excellent 5-HT1A affinity. The final compounds, 4a, 8a, and 8b, were selected according to predictions of in silico pharmacokinetics, docking analysis, and molecular dynamics in conjunction with physical properties, and metabolic stability. The accentuated molecules could serve as a lead compound for developing 5-HT1A drug-like molecules for depression treatment.     

Efficiency of antidepressant drugs as monoamine reuptake inhibitors: analysis of the hydrophobicity influence using biopartitioning micellar chromatographic data

The reuptake blockade of biogenic amines by antidepressants is related not only to their therapeutics effects, but also to their side effects and potential drug-drug interactions. As an alternative to classical quantitative structure-activity relationships studies, in this work we propose different quantitative retention-activity relationships (QRAR) models that are able to describe the monoamine reuptake inhibition by antidepressants. The retention of compounds is measured using a biopartitioning micellar chromatography (BMC) system that can simulate the same hydrophobic, electronic and steric molecular interactions as those that condition drug activity. Since all the compounds considered in this work are structurally related because all of them share the same molecular features as the corresponding basic pharmacophore, the results obtained show that there is a retention range in which antidepressants present the highest monoamine reuptake inhibitor potency.